Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
GlaxoSmithKline
$720 million |
| gptkbp:acquisitionYear |
2008
|
| gptkbp:ceased_operations |
2013
|
| gptkbp:focusesOn |
aging research
metabolic diseases sirtuin activators |
| gptkbp:foundedBy |
gptkb:Richard_Pops
gptkb:Richard_Aldrich gptkb:David_Sinclair gptkb:Christoph_Westphal gptkb:Michelle_Dipp |
| gptkbp:foundedIn |
2004
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sirtris Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:SRT501
|
| gptkbp:parentCompany |
GlaxoSmithKline
|
| gptkbp:SRT501Is |
resveratrol formulation
|
| gptkbp:website |
http://www.sirtrispharma.com/
|
| gptkbp:bfsParent |
gptkb:David_Sinclair
|
| gptkbp:bfsLayer |
5
|